nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Nicotine—ulcerative colitis	0.106	0.438	CbGbCtD
Methylnaltrexone—CYP2D6—Cholecalciferol—ulcerative colitis	0.0949	0.392	CbGbCtD
Methylnaltrexone—CYP2D6—Dexamethasone—ulcerative colitis	0.0411	0.17	CbGbCtD
Methylnaltrexone—Redness—Nicotine—ulcerative colitis	0.0374	0.058	CcSEcCtD
Methylnaltrexone—Naloxone—TLR4—ulcerative colitis	0.0341	0.565	CrCbGaD
Methylnaltrexone—Redness—Hydrocortisone—ulcerative colitis	0.0149	0.0231	CcSEcCtD
Methylnaltrexone—Stinging—Prednisolone—ulcerative colitis	0.0127	0.0197	CcSEcCtD
Methylnaltrexone—Stinging—Hydrocortisone—ulcerative colitis	0.0124	0.0193	CcSEcCtD
Methylnaltrexone—Stinging—Triamcinolone—ulcerative colitis	0.0117	0.0181	CcSEcCtD
Methylnaltrexone—Erythema—Nicotine—ulcerative colitis	0.011	0.0171	CcSEcCtD
Methylnaltrexone—Flatulence—Nicotine—ulcerative colitis	0.0109	0.0169	CcSEcCtD
Methylnaltrexone—Stinging—Dexamethasone—ulcerative colitis	0.0106	0.0165	CcSEcCtD
Methylnaltrexone—Stinging—Betamethasone—ulcerative colitis	0.0106	0.0165	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—ulcerative colitis	0.00963	0.0149	CcSEcCtD
Methylnaltrexone—Oedema—Mercaptopurine—ulcerative colitis	0.0093	0.0144	CcSEcCtD
Methylnaltrexone—Skin disorder—Mercaptopurine—ulcerative colitis	0.00903	0.014	CcSEcCtD
Methylnaltrexone—Oedema—Nicotine—ulcerative colitis	0.00901	0.014	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Nicotine—ulcerative colitis	0.00884	0.0137	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Nicotine—ulcerative colitis	0.00871	0.0135	CcSEcCtD
Methylnaltrexone—Hydromorphone—PTGS1—ulcerative colitis	0.00831	0.137	CrCbGaD
Methylnaltrexone—Gastrointestinal disorder—Mercaptopurine—ulcerative colitis	0.00803	0.0125	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Nicotine—ulcerative colitis	0.00778	0.0121	CcSEcCtD
Methylnaltrexone—Pain—Nicotine—ulcerative colitis	0.0077	0.012	CcSEcCtD
Methylnaltrexone—Flatulence—Budesonide—ulcerative colitis	0.00749	0.0116	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Nicotine—ulcerative colitis	0.00737	0.0114	CcSEcCtD
Methylnaltrexone—Abdominal pain—Nicotine—ulcerative colitis	0.00712	0.0111	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Budesonide—ulcerative colitis	0.00643	0.00997	CcSEcCtD
Methylnaltrexone—Diarrhoea—Mercaptopurine—ulcerative colitis	0.00636	0.00987	CcSEcCtD
Methylnaltrexone—Erythema—Mesalazine—ulcerative colitis	0.00618	0.00959	CcSEcCtD
Methylnaltrexone—Diarrhoea—Nicotine—ulcerative colitis	0.00616	0.00957	CcSEcCtD
Methylnaltrexone—Flatulence—Mesalazine—ulcerative colitis	0.00609	0.00945	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Budesonide—ulcerative colitis	0.00608	0.00944	CcSEcCtD
Methylnaltrexone—Skin disorder—Budesonide—ulcerative colitis	0.00603	0.00935	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Budesonide—ulcerative colitis	0.006	0.00931	CcSEcCtD
Methylnaltrexone—Dizziness—Nicotine—ulcerative colitis	0.00596	0.00924	CcSEcCtD
Methylnaltrexone—Vomiting—Mercaptopurine—ulcerative colitis	0.00591	0.00917	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—ulcerative colitis	0.00574	0.00891	CcSEcCtD
Methylnaltrexone—Vomiting—Nicotine—ulcerative colitis	0.00573	0.00889	CcSEcCtD
Methylnaltrexone—Naltrexone—ABCB1—ulcerative colitis	0.00558	0.0922	CrCbGaD
Methylnaltrexone—Nausea—Mercaptopurine—ulcerative colitis	0.00552	0.00857	CcSEcCtD
Methylnaltrexone—Skin disorder—Azathioprine—ulcerative colitis	0.00538	0.00835	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Budesonide—ulcerative colitis	0.00536	0.00831	CcSEcCtD
Methylnaltrexone—Nausea—Nicotine—ulcerative colitis	0.00535	0.0083	CcSEcCtD
Methylnaltrexone—Pain—Budesonide—ulcerative colitis	0.00531	0.00823	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—ulcerative colitis	0.00523	0.00811	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Budesonide—ulcerative colitis	0.00507	0.00787	CcSEcCtD
Methylnaltrexone—Oedema—Mesalazine—ulcerative colitis	0.00505	0.00783	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Mesalazine—ulcerative colitis	0.00495	0.00768	CcSEcCtD
Methylnaltrexone—Abdominal pain—Budesonide—ulcerative colitis	0.00491	0.00761	CcSEcCtD
Methylnaltrexone—Skin disorder—Mesalazine—ulcerative colitis	0.0049	0.00761	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Mesalazine—ulcerative colitis	0.00488	0.00757	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Azathioprine—ulcerative colitis	0.00478	0.00742	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Azathioprine—ulcerative colitis	0.00453	0.00703	CcSEcCtD
Methylnaltrexone—Erythema—Prednisolone—ulcerative colitis	0.0045	0.00699	CcSEcCtD
Methylnaltrexone—Erythema—Hydrocortisone—ulcerative colitis	0.0044	0.00682	CcSEcCtD
Methylnaltrexone—Abdominal pain—Azathioprine—ulcerative colitis	0.00438	0.0068	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Mesalazine—ulcerative colitis	0.00436	0.00676	CcSEcCtD
Methylnaltrexone—Pain—Mesalazine—ulcerative colitis	0.00432	0.0067	CcSEcCtD
Methylnaltrexone—Naloxone—ALB—ulcerative colitis	0.00426	0.0705	CrCbGaD
Methylnaltrexone—Diarrhoea—Budesonide—ulcerative colitis	0.00425	0.00659	CcSEcCtD
Methylnaltrexone—Erythema—Triamcinolone—ulcerative colitis	0.00414	0.00642	CcSEcCtD
Methylnaltrexone—Erythema—Methylprednisolone—ulcerative colitis	0.00413	0.00641	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Mesalazine—ulcerative colitis	0.00413	0.0064	CcSEcCtD
Methylnaltrexone—Dizziness—Budesonide—ulcerative colitis	0.0041	0.00637	CcSEcCtD
Methylnaltrexone—Buprenorphine—ABCB1—ulcerative colitis	0.0041	0.0678	CrCbGaD
Methylnaltrexone—Naloxone—ABCB1—ulcerative colitis	0.00407	0.0673	CrCbGaD
Methylnaltrexone—Abdominal pain—Mesalazine—ulcerative colitis	0.00399	0.00619	CcSEcCtD
Methylnaltrexone—Vomiting—Budesonide—ulcerative colitis	0.00395	0.00612	CcSEcCtD
Methylnaltrexone—Diarrhoea—Azathioprine—ulcerative colitis	0.00379	0.00588	CcSEcCtD
Methylnaltrexone—Erythema—Dexamethasone—ulcerative colitis	0.00376	0.00583	CcSEcCtD
Methylnaltrexone—Erythema—Betamethasone—ulcerative colitis	0.00376	0.00583	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—ulcerative colitis	0.00372	0.00577	CcSEcCtD
Methylnaltrexone—Nausea—Budesonide—ulcerative colitis	0.00369	0.00572	CcSEcCtD
Methylnaltrexone—Oedema—Prednisolone—ulcerative colitis	0.00367	0.0057	CcSEcCtD
Methylnaltrexone—Dizziness—Azathioprine—ulcerative colitis	0.00366	0.00568	CcSEcCtD
Methylnaltrexone—Oedema—Hydrocortisone—ulcerative colitis	0.00359	0.00557	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Prednisolone—ulcerative colitis	0.00355	0.00551	CcSEcCtD
Methylnaltrexone—Vomiting—Azathioprine—ulcerative colitis	0.00352	0.00547	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Hydrocortisone—ulcerative colitis	0.00352	0.00546	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ulcerative colitis	0.00349	0.00542	CcSEcCtD
Methylnaltrexone—Skin disorder—Hydrocortisone—ulcerative colitis	0.00349	0.00541	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Hydrocortisone—ulcerative colitis	0.00347	0.00538	CcSEcCtD
Methylnaltrexone—Diarrhoea—Mesalazine—ulcerative colitis	0.00345	0.00536	CcSEcCtD
Methylnaltrexone—Oedema—Triamcinolone—ulcerative colitis	0.00338	0.00524	CcSEcCtD
Methylnaltrexone—Dizziness—Mesalazine—ulcerative colitis	0.00334	0.00518	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Methylprednisolone—ulcerative colitis	0.00331	0.00513	CcSEcCtD
Methylnaltrexone—Nausea—Azathioprine—ulcerative colitis	0.00329	0.00511	CcSEcCtD
Methylnaltrexone—Skin disorder—Methylprednisolone—ulcerative colitis	0.00327	0.00508	CcSEcCtD
Methylnaltrexone—Erythema—Prednisone—ulcerative colitis	0.00327	0.00508	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Triamcinolone—ulcerative colitis	0.00327	0.00507	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Methylprednisolone—ulcerative colitis	0.00326	0.00506	CcSEcCtD
Methylnaltrexone—Vomiting—Mesalazine—ulcerative colitis	0.00321	0.00498	CcSEcCtD
Methylnaltrexone—Pain—Prednisolone—ulcerative colitis	0.00314	0.00488	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Hydrocortisone—ulcerative colitis	0.0031	0.00481	CcSEcCtD
Methylnaltrexone—Pain—Hydrocortisone—ulcerative colitis	0.00307	0.00476	CcSEcCtD
Methylnaltrexone—Oedema—Betamethasone—ulcerative colitis	0.00307	0.00476	CcSEcCtD
Methylnaltrexone—Oedema—Dexamethasone—ulcerative colitis	0.00307	0.00476	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Betamethasone—ulcerative colitis	0.00301	0.00467	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Dexamethasone—ulcerative colitis	0.00301	0.00467	CcSEcCtD
Methylnaltrexone—Nausea—Mesalazine—ulcerative colitis	0.003	0.00465	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Dexamethasone—ulcerative colitis	0.00296	0.0046	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Betamethasone—ulcerative colitis	0.00296	0.0046	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Hydrocortisone—ulcerative colitis	0.00293	0.00455	CcSEcCtD
Methylnaltrexone—Pain—Triamcinolone—ulcerative colitis	0.00289	0.00448	CcSEcCtD
Methylnaltrexone—Abdominal pain—Hydrocortisone—ulcerative colitis	0.00284	0.0044	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ulcerative colitis	0.00277	0.00429	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Methylprednisolone—ulcerative colitis	0.00276	0.00428	CcSEcCtD
Methylnaltrexone—Oedema—Prednisone—ulcerative colitis	0.00267	0.00414	CcSEcCtD
Methylnaltrexone—Abdominal pain—Methylprednisolone—ulcerative colitis	0.00267	0.00414	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Dexamethasone—ulcerative colitis	0.00265	0.00411	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Betamethasone—ulcerative colitis	0.00265	0.00411	CcSEcCtD
Methylnaltrexone—Pain—Dexamethasone—ulcerative colitis	0.00262	0.00407	CcSEcCtD
Methylnaltrexone—Pain—Betamethasone—ulcerative colitis	0.00262	0.00407	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Prednisone—ulcerative colitis	0.00262	0.00406	CcSEcCtD
Methylnaltrexone—Skin disorder—Prednisone—ulcerative colitis	0.00259	0.00402	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Prednisone—ulcerative colitis	0.00258	0.004	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Betamethasone—ulcerative colitis	0.00251	0.00389	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Dexamethasone—ulcerative colitis	0.00251	0.00389	CcSEcCtD
Methylnaltrexone—Diarrhoea—Hydrocortisone—ulcerative colitis	0.00246	0.00381	CcSEcCtD
Methylnaltrexone—Dizziness—Prednisolone—ulcerative colitis	0.00243	0.00377	CcSEcCtD
Methylnaltrexone—Abdominal pain—Dexamethasone—ulcerative colitis	0.00242	0.00376	CcSEcCtD
Methylnaltrexone—Abdominal pain—Betamethasone—ulcerative colitis	0.00242	0.00376	CcSEcCtD
Methylnaltrexone—Dizziness—Hydrocortisone—ulcerative colitis	0.00237	0.00368	CcSEcCtD
Methylnaltrexone—Diarrhoea—Methylprednisolone—ulcerative colitis	0.00231	0.00358	CcSEcCtD
Methylnaltrexone—Vomiting—Hydrocortisone—ulcerative colitis	0.00228	0.00354	CcSEcCtD
Methylnaltrexone—Dizziness—Triamcinolone—ulcerative colitis	0.00223	0.00347	CcSEcCtD
Methylnaltrexone—Dizziness—Methylprednisolone—ulcerative colitis	0.00223	0.00346	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Prednisone—ulcerative colitis	0.00218	0.00339	CcSEcCtD
Methylnaltrexone—Nausea—Prednisolone—ulcerative colitis	0.00218	0.00339	CcSEcCtD
Methylnaltrexone—Vomiting—Triamcinolone—ulcerative colitis	0.00215	0.00333	CcSEcCtD
Methylnaltrexone—Vomiting—Methylprednisolone—ulcerative colitis	0.00214	0.00333	CcSEcCtD
Methylnaltrexone—Nausea—Hydrocortisone—ulcerative colitis	0.00213	0.00331	CcSEcCtD
Methylnaltrexone—Abdominal pain—Prednisone—ulcerative colitis	0.00211	0.00327	CcSEcCtD
Methylnaltrexone—Diarrhoea—Betamethasone—ulcerative colitis	0.0021	0.00325	CcSEcCtD
Methylnaltrexone—Diarrhoea—Dexamethasone—ulcerative colitis	0.0021	0.00325	CcSEcCtD
Methylnaltrexone—Dizziness—Betamethasone—ulcerative colitis	0.00203	0.00315	CcSEcCtD
Methylnaltrexone—Dizziness—Dexamethasone—ulcerative colitis	0.00203	0.00315	CcSEcCtD
Methylnaltrexone—Nausea—Triamcinolone—ulcerative colitis	0.00201	0.00311	CcSEcCtD
Methylnaltrexone—Nausea—Methylprednisolone—ulcerative colitis	0.002	0.00311	CcSEcCtD
Methylnaltrexone—Vomiting—Dexamethasone—ulcerative colitis	0.00195	0.00302	CcSEcCtD
Methylnaltrexone—Vomiting—Betamethasone—ulcerative colitis	0.00195	0.00302	CcSEcCtD
Methylnaltrexone—Diarrhoea—Prednisone—ulcerative colitis	0.00183	0.00283	CcSEcCtD
Methylnaltrexone—Nausea—Dexamethasone—ulcerative colitis	0.00182	0.00283	CcSEcCtD
Methylnaltrexone—Nausea—Betamethasone—ulcerative colitis	0.00182	0.00283	CcSEcCtD
Methylnaltrexone—Dizziness—Prednisone—ulcerative colitis	0.00177	0.00274	CcSEcCtD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—GPR35—ulcerative colitis	0.00176	0.033	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide GPCRs—CXCR1—ulcerative colitis	0.00171	0.0321	CbGpPWpGaD
Methylnaltrexone—Vomiting—Prednisone—ulcerative colitis	0.0017	0.00263	CcSEcCtD
Methylnaltrexone—CYP2D6—Codeine and Morphine Metabolism—ABCB1—ulcerative colitis	0.00169	0.0317	CbGpPWpGaD
Methylnaltrexone—Nausea—Prednisone—ulcerative colitis	0.00159	0.00246	CcSEcCtD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—GPR35—ulcerative colitis	0.00148	0.0279	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide GPCRs—CXCR1—ulcerative colitis	0.00144	0.0271	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide GPCRs—CXCR2—ulcerative colitis	0.00134	0.0251	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide GPCRs—CCR6—ulcerative colitis	0.00126	0.0236	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide GPCRs—CXCR2—ulcerative colitis	0.00113	0.0212	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide GPCRs—CCR6—ulcerative colitis	0.00106	0.0199	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CXCR1—ulcerative colitis	0.000804	0.0151	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—IL17A—ulcerative colitis	0.000788	0.0148	CbGpPWpGaD
Methylnaltrexone—OPRM1—Opioid Signalling—CALM3—ulcerative colitis	0.000772	0.0145	CbGpPWpGaD
Methylnaltrexone—OPRM1—IL4-mediated signaling events—IL10—ulcerative colitis	0.000722	0.0135	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CCL20—ulcerative colitis	0.000706	0.0132	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—RIPK2—ulcerative colitis	0.000699	0.0131	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CXCR1—ulcerative colitis	0.000679	0.0128	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CXCR1—ulcerative colitis	0.000678	0.0127	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR1—ulcerative colitis	0.000629	0.0118	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CXCR2—ulcerative colitis	0.000629	0.0118	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCL20—ulcerative colitis	0.000596	0.0112	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CCL20—ulcerative colitis	0.000595	0.0112	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CCR6—ulcerative colitis	0.000591	0.0111	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CXCR1—ulcerative colitis	0.000573	0.0108	CbGpPWpGaD
Methylnaltrexone—OPRM1—Opioid Signalling—ADCY5—ulcerative colitis	0.00056	0.0105	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR1—ulcerative colitis	0.000539	0.0101	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR1—ulcerative colitis	0.000532	0.00998	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CXCR2—ulcerative colitis	0.000532	0.00998	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CXCR2—ulcerative colitis	0.000531	0.00996	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CCL20—ulcerative colitis	0.000503	0.00945	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCR6—ulcerative colitis	0.0005	0.00938	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CCR6—ulcerative colitis	0.000499	0.00937	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR2—ulcerative colitis	0.000492	0.00924	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—GHRL—ulcerative colitis	0.000477	0.00895	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL20—ulcerative colitis	0.000473	0.00889	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR6—ulcerative colitis	0.000463	0.00869	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR1—ulcerative colitis	0.000456	0.00855	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CXCR2—ulcerative colitis	0.000448	0.00842	CbGpPWpGaD
Methylnaltrexone—OPRM1—IL4-mediated signaling events—JAK2—ulcerative colitis	0.000432	0.00811	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR2—ulcerative colitis	0.000422	0.00792	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CCR6—ulcerative colitis	0.000422	0.00792	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR2—ulcerative colitis	0.000416	0.00781	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCR1—ulcerative colitis	0.000411	0.00771	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—PTGER4—ulcerative colitis	0.000408	0.00765	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—GHRL—ulcerative colitis	0.000403	0.00756	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—ulcerative colitis	0.0004	0.00751	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR6—ulcerative colitis	0.000397	0.00745	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR6—ulcerative colitis	0.000391	0.00735	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—ulcerative colitis	0.000391	0.00733	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCL20—ulcerative colitis	0.00036	0.00677	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR2—ulcerative colitis	0.000357	0.00669	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ulcerative colitis	0.000349	0.00656	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCR1—ulcerative colitis	0.000347	0.00651	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—PTGER4—ulcerative colitis	0.000345	0.00647	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR6—ulcerative colitis	0.000335	0.00629	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCR2—ulcerative colitis	0.000321	0.00603	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—GHRL—ulcerative colitis	0.00032	0.006	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—RELA—ulcerative colitis	0.000311	0.00583	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—ADRB2—ulcerative colitis	0.000309	0.0058	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCL20—ulcerative colitis	0.000305	0.00572	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—CD4—ulcerative colitis	0.000304	0.00571	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCR6—ulcerative colitis	0.000302	0.00567	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ulcerative colitis	0.000295	0.00554	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Melatonin metabolism and effects—NFKB1—ulcerative colitis	0.000287	0.00538	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—ADCY5—ulcerative colitis	0.000283	0.0053	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—IL1B—ulcerative colitis	0.000281	0.00527	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCR2—ulcerative colitis	0.000272	0.0051	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—GHRL—ulcerative colitis	0.00027	0.00507	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—PTGER4—ulcerative colitis	0.000266	0.00499	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ADRB2—ulcerative colitis	0.000265	0.00497	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—NFKB1—ulcerative colitis	0.000262	0.00492	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—ADRB2—ulcerative colitis	0.000261	0.0049	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCR6—ulcerative colitis	0.000255	0.00479	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—GHRL—ulcerative colitis	0.000244	0.00457	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—ADCY5—ulcerative colitis	0.000239	0.00448	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCR1—ulcerative colitis	0.000232	0.00436	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—PTGER4—ulcerative colitis	0.000225	0.00422	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB2—ulcerative colitis	0.000224	0.0042	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—TGFB1—ulcerative colitis	0.000218	0.0041	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCR1—ulcerative colitis	0.000211	0.00396	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—PTGS1—ulcerative colitis	0.000207	0.00389	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—GHRL—ulcerative colitis	0.000206	0.00386	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCL20—ulcerative colitis	0.000204	0.00382	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—ADRB2—ulcerative colitis	0.000202	0.00378	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCR1—ulcerative colitis	0.000196	0.00368	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GNA12—ulcerative colitis	0.000192	0.0036	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CXCL8—ulcerative colitis	0.000191	0.00358	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL20—ulcerative colitis	0.000185	0.00347	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCR2—ulcerative colitis	0.000182	0.00341	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCR1—ulcerative colitis	0.000178	0.00334	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GNA12—ulcerative colitis	0.000174	0.00326	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCL20—ulcerative colitis	0.000172	0.00323	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCR6—ulcerative colitis	0.000171	0.0032	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—ADRB2—ulcerative colitis	0.00017	0.0032	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCR2—ulcerative colitis	0.000165	0.0031	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—IL6—ulcerative colitis	0.000164	0.00309	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GNA12—ulcerative colitis	0.000162	0.00304	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CXCL8—ulcerative colitis	0.000161	0.00302	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CXCL8—ulcerative colitis	0.000161	0.00302	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL20—ulcerative colitis	0.000156	0.00293	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCR6—ulcerative colitis	0.000155	0.00291	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCR2—ulcerative colitis	0.000153	0.00288	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SEL1L—ulcerative colitis	0.000151	0.00284	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PTGER4—ulcerative colitis	0.00015	0.00282	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GNA12—ulcerative colitis	0.000147	0.00276	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCR6—ulcerative colitis	0.000144	0.00271	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCR2—ulcerative colitis	0.000139	0.00262	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GHRL—ulcerative colitis	0.000138	0.00258	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PTGER4—ulcerative colitis	0.000136	0.00256	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CXCL8—ulcerative colitis	0.000136	0.00255	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCR6—ulcerative colitis	0.000131	0.00246	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—ulcerative colitis	0.000128	0.0024	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SEL1L—ulcerative colitis	0.000128	0.0024	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PTGER4—ulcerative colitis	0.000127	0.00238	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GHRL—ulcerative colitis	0.000125	0.00235	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCR1—ulcerative colitis	0.000124	0.00234	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CALM3—ulcerative colitis	0.000121	0.00227	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GHRL—ulcerative colitis	0.000116	0.00218	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PTGER4—ulcerative colitis	0.000115	0.00217	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—ADRB2—ulcerative colitis	0.000114	0.00214	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL20—ulcerative colitis	0.000109	0.00205	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—ulcerative colitis	0.000108	0.00203	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GHRL—ulcerative colitis	0.000106	0.00198	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCR1—ulcerative colitis	0.000105	0.00197	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ADRB2—ulcerative colitis	0.000103	0.00194	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GNA12—ulcerative colitis	0.000103	0.00193	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CALM3—ulcerative colitis	0.000102	0.00192	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCR2—ulcerative colitis	9.74e-05	0.00183	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCL8—ulcerative colitis	9.73e-05	0.00183	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—ADCY5—ulcerative colitis	9.67e-05	0.00181	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—ADRB2—ulcerative colitis	9.63e-05	0.00181	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL20—ulcerative colitis	9.24e-05	0.00173	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCR6—ulcerative colitis	9.16e-05	0.00172	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ADCY5—ulcerative colitis	8.78e-05	0.00165	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ADRB2—ulcerative colitis	8.74e-05	0.00164	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GNA12—ulcerative colitis	8.68e-05	0.00163	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAML2—ulcerative colitis	8.68e-05	0.00163	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CHP1—ulcerative colitis	8.5e-05	0.0016	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCR2—ulcerative colitis	8.23e-05	0.00155	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCL8—ulcerative colitis	8.23e-05	0.00154	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—ADCY5—ulcerative colitis	8.17e-05	0.00153	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTGER4—ulcerative colitis	8.06e-05	0.00151	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR6—ulcerative colitis	7.74e-05	0.00145	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ADCY5—ulcerative colitis	7.42e-05	0.00139	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GHRL—ulcerative colitis	7.38e-05	0.00139	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—DLD—ulcerative colitis	7.34e-05	0.00138	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAML2—ulcerative colitis	7.34e-05	0.00138	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CALM3—ulcerative colitis	7.15e-05	0.00134	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RIPK2—ulcerative colitis	7.04e-05	0.00132	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTGER4—ulcerative colitis	6.81e-05	0.00128	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GHRL—ulcerative colitis	6.24e-05	0.00117	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADRB2—ulcerative colitis	6.11e-05	0.00115	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CALM3—ulcerative colitis	6.04e-05	0.00113	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—JAK2—ulcerative colitis	6.03e-05	0.00113	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RIPK2—ulcerative colitis	5.95e-05	0.00112	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL8—ulcerative colitis	5.5e-05	0.00103	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—JAK2—ulcerative colitis	5.47e-05	0.00103	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—IL2—ulcerative colitis	5.26e-05	0.000987	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADCY5—ulcerative colitis	5.19e-05	0.000974	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRB2—ulcerative colitis	5.16e-05	0.000969	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—JAK2—ulcerative colitis	5.09e-05	0.000956	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL8—ulcerative colitis	5e-05	0.000938	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL2—ulcerative colitis	4.77e-05	0.000896	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL8—ulcerative colitis	4.65e-05	0.000873	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—JAK2—ulcerative colitis	4.63e-05	0.000868	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—IL2—ulcerative colitis	4.44e-05	0.000834	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADCY5—ulcerative colitis	4.38e-05	0.000823	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL8—ulcerative colitis	4.22e-05	0.000793	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL2—ulcerative colitis	4.04e-05	0.000757	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS1—ulcerative colitis	3.55e-05	0.000666	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JAK2—ulcerative colitis	3.23e-05	0.000607	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CALM3—ulcerative colitis	3.19e-05	0.0006	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RELA—ulcerative colitis	3.13e-05	0.000588	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL8—ulcerative colitis	2.95e-05	0.000554	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL2—ulcerative colitis	2.82e-05	0.000529	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—ulcerative colitis	2.81e-05	0.000527	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JAK2—ulcerative colitis	2.73e-05	0.000513	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—ulcerative colitis	2.67e-05	0.000501	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RELA—ulcerative colitis	2.65e-05	0.000497	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NFKB1—ulcerative colitis	2.64e-05	0.000496	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL8—ulcerative colitis	2.49e-05	0.000468	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCB1—ulcerative colitis	2.48e-05	0.000466	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL2—ulcerative colitis	2.38e-05	0.000447	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT3—ulcerative colitis	2.37e-05	0.000445	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—ulcerative colitis	2.37e-05	0.000445	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADCY5—ulcerative colitis	2.32e-05	0.000435	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—ulcerative colitis	2.26e-05	0.000423	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NFKB1—ulcerative colitis	2.23e-05	0.000419	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFB1—ulcerative colitis	2.2e-05	0.000413	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT3—ulcerative colitis	2.01e-05	0.000377	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFB1—ulcerative colitis	1.86e-05	0.000349	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TP53—ulcerative colitis	1.81e-05	0.00034	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARG—ulcerative colitis	1.73e-05	0.000324	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—ulcerative colitis	1.66e-05	0.000311	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALB—ulcerative colitis	1.55e-05	0.000292	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TP53—ulcerative colitis	1.53e-05	0.000287	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—ulcerative colitis	1.4e-05	0.000263	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—ulcerative colitis	1.36e-05	0.000255	CbGpPWpGaD
